Suit to Test Rights of Physicians to Receive Info on Off-Label Drug Use

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 5
Volume 4
Issue 5

WASHINGTON--The Washington Legal Foundation (WLF), a public interest group, has claimed that the FDA violated the First Amendment rights of physicians by denying them access to information about the off-label use of certain oncologic drugs.

WASHINGTON--The Washington Legal Foundation (WLF), a public interestgroup, has claimed that the FDA violated the First Amendment rightsof physicians by denying them access to information about theoff-label use of certain oncologic drugs.

WLF's suit arises from an action taken by the FDA that preventedBristol-Myers Squibb Co.from giving physicians complimentary copiesof The Chemotherapy Sourcebook, edited by Michael Perry, and chaptersfrom Cancer: Principles and Practice of Oncology, by Vincent DeVita,Samuel Hellman, and Steven Rosenberg.

Federal Judge Royce Lamberth denied the FDA's motion to dismissthe suit, thus clearing the way for a trial, which will be thefirst constitutional test of the agency's criteria to discouragewhat it views as improper promotion of drugs by means of distributionof legitimate medical educational material.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
According to Jorge Nieva, MD, there are a multitude of things that can be explored to enhance the treatment landscape for lung cancer.
5 experts are featured in this series
2 experts are featured in this series.
5 experts are featured in this series
2 experts are featured in this series.
Taletrectinib showed improved efficacy in patients with ROS1-positive non–small cell lung cancer who were treatment-naïve.
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
Related Content